Altimmune (ALT) Competitors $3.87 +0.30 (+8.40%) Closing price 04:00 PM EasternExtended Trading$3.91 +0.04 (+1.14%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALT vs. NTLA, ETNB, XERS, ABCL, PGEN, EVO, TLRY, RCUS, WVE, and STOKShould you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Intellia Therapeutics (NTLA), 89BIO (ETNB), Xeris Biopharma (XERS), AbCellera Biologics (ABCL), Precigen (PGEN), Evotec (EVO), Tilray Brands (TLRY), Arcus Biosciences (RCUS), WAVE Life Sciences (WVE), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Altimmune vs. Its Competitors Intellia Therapeutics 89BIO Xeris Biopharma AbCellera Biologics Precigen Evotec Tilray Brands Arcus Biosciences WAVE Life Sciences Stoke Therapeutics Altimmune (NASDAQ:ALT) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership. Is ALT or NTLA more profitable? Intellia Therapeutics has a net margin of -908.48% compared to Altimmune's net margin of -438,730.03%. Intellia Therapeutics' return on equity of -57.48% beat Altimmune's return on equity.Company Net Margins Return on Equity Return on Assets Altimmune-438,730.03% -62.63% -55.29% Intellia Therapeutics -908.48%-57.48%-45.04% Do institutionals and insiders have more ownership in ALT or NTLA? 78.1% of Altimmune shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 4.4% of Altimmune shares are held by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, ALT or NTLA? Altimmune has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500. Which has preferable earnings & valuation, ALT or NTLA? Altimmune has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAltimmune$20K17,078.31-$95.06M-$1.18-3.28Intellia Therapeutics$52.86M32.72-$519.02M-$4.69-3.43 Does the media refer more to ALT or NTLA? In the previous week, Altimmune had 13 more articles in the media than Intellia Therapeutics. MarketBeat recorded 24 mentions for Altimmune and 11 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.98 beat Altimmune's score of 0.14 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 2 Very Positive mention(s) 0 Positive mention(s) 21 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ALT or NTLA? Altimmune currently has a consensus price target of $17.40, indicating a potential upside of 349.61%. Intellia Therapeutics has a consensus price target of $27.11, indicating a potential upside of 68.29%. Given Altimmune's stronger consensus rating and higher probable upside, equities analysts clearly believe Altimmune is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Altimmune 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.56 SummaryAltimmune and Intellia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALT vs. The Competition Export to ExcelMetricAltimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$315.08M$2.55B$5.76B$10.29BDividend YieldN/A57.28%5.74%4.60%P/E Ratio-3.2823.4276.8626.96Price / Sales17,078.31717.16539.94127.44Price / CashN/A169.7137.1760.63Price / Book2.225.4313.836.37Net Income-$95.06M$32.95M$3.29B$271.46M7 Day Performance4.88%0.84%0.93%2.35%1 Month Performance8.71%6.04%5.31%7.78%1 Year Performance-47.91%-0.89%84.25%32.27% Altimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTAltimmune2.7689 of 5 stars$3.87+8.4%$17.40+349.6%-52.8%$315.08M$20K-3.2850High Trading VolumeNTLAIntellia Therapeutics4.5066 of 5 stars$11.84-1.8%$29.05+145.4%-45.0%$1.27B$57.88M-2.52600News CoverageOptions VolumeGap UpETNB89BIO2.6572 of 5 stars$8.57-3.4%$28.00+226.7%-3.2%$1.27BN/A-2.3740Trending NewsGap UpXERSXeris Biopharma2.8537 of 5 stars$7.77-1.0%$7.08-8.8%+164.5%$1.25B$203.07M-37.00290ABCLAbCellera Biologics3.0643 of 5 stars$4.17-1.2%$8.00+91.8%+67.4%$1.25B$28.83M-7.58500News CoveragePGENPrecigen4.5413 of 5 stars$4.16-4.6%$8.25+98.3%+283.1%$1.24B$3.92M-9.90190EVOEvotec1.889 of 5 stars$3.49+0.3%$5.40+54.7%+0.0%$1.24B$862.40M0.004,827News CoveragePositive NewsGap UpTLRYTilray Brands3.0534 of 5 stars$1.12-6.1%$1.94+73.4%-34.3%$1.23B$821.31M-0.482,842RCUSArcus Biosciences2.004 of 5 stars$11.43-6.3%$21.14+85.0%-28.2%$1.22B$258M-3.60500Positive NewsWVEWAVE Life Sciences4.1959 of 5 stars$7.58-8.6%$20.33+168.2%+19.1%$1.21B$108.30M-8.42240STOKStoke Therapeutics3.8468 of 5 stars$21.99+6.3%$25.57+16.3%+50.4%$1.21B$36.56M25.87100Positive News Related Companies and Tools Related Companies Intellia Therapeutics Alternatives 89BIO Alternatives Xeris Biopharma Alternatives AbCellera Biologics Alternatives Precigen Alternatives Evotec Alternatives Tilray Brands Alternatives Arcus Biosciences Alternatives WAVE Life Sciences Alternatives Stoke Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALT) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
